We have identified the genetic sequences of TCRs that target tumor antigens. We are testing genetically engineered T cells that express these TCRs for the treatment of patients with cancer. Our research is focused and on understanding response and resistance to these treatments with the goal to use this knowledge to develop more effective treatments. This work includes the discovery of technologies to identify biomarkers of response, enhance the efficacy of therapeutic T cells, and target new tumor antigens.
|Hinrichs, Christian S (2018) Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy. J Clin Invest 128:1261-1263|
|Hinrichs, Christian S (2016) Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res 22:1559-64|
|Draper, Lindsey M; Kwong, Mei Li M; Gros, Alena et al. (2015) Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res 21:4431-9|
|Hinrichs, Christian S; Rosenberg, Steven A (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56-71|
|Hinrichs, Christian S; Restifo, Nicholas P (2013) Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 31:999-1008|